TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04089397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Therapy
Description: Five weeks of light therapy, with 3 weekly sessions of 30 minutes, to be performed between 8:00 to 10:00, the days of dialysis
Study: NCT03837951

Intervention type: OTHER
Intervention: Figure-of-eight tape measure measurements on both hands
Description: Tape measure is wrapped around the wrist and hand and a measurement reading is taken. this is repeated 3 times.

Intervention type: OTHER
Intervention: Figure-of-eight tape measure measurements on both hands
Description: Tape measure is wrapped around the wrist and hand and a measurement reading is taken. this is repeated 3 times.

Intervention type: OTHER
Intervention: Volumeter measurements
Description: Volumeter measurements to uninjured participants had 3 measurements taken of each hand.
Study: NCT00566540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients will receive Cisplatin (30 mg/m2 i.v.) daily x 3 days in week 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients will receive Paclitaxel (45 mg/m2i.v.) infusion over 3 hours during weeks 7,8,9,10

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation
Description: Patients will receive Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation to tumor and involved regional nodes 20Gy over 10 daily (M-F) treatments (2 Gy Fractions with 6 millivolts photons)week 1 and 2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Triple endoscopy and biopsy
Description: Resection of the primary tumor: Patients must have surgery performed according to the following surgical guidelines. The extent of the surgical resection will be dictated by the extent of the tumor at the time of initial evaluation. The primary lesion must be widely excised using accepted criteria for adequate excision depending on the region involved. All patients will undergo percutaneous endoscopic gastrostomy tube placement at the time of endoscopy and biopsies.
Study: NCT00512486

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-563
Description: BIW-8405/MEDI-563 administered at one of five dose levels:~* 0.03 mg/kg intravenous injection~* 0.1 mg/kg intravenous injection~* 0.3 mg/kg intravenous injection~* 1.0 mg/kg intravenous injection~* 3.0 mg/kg intravenous injection~Following the -3.0 mg/kg dose level,~BIW-8405/MEDI-563 administered at one of two lower dose levels:~0.003 mg/kg intravenous injection 0.0003 mg/kg intravenous injection
Study: NCT00648999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir
Description: lopinavir/ritonavir 400 mg/100 mg bid 48 weeks of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir
Description: lopinavir/ritonavir 400 mg/100 mg bid 48 weeks of treatment
Study: NCT03882151

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: electrical source imaging
Description: automated analysis of surface EEG with electrocal source imaging
Study: NCT03833791

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education and modifying diet
Description: The control group maintains a sedentary lifestyle and is only subjected to follow a hypocaloric diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education, modifying diet and physical activity prescription
Description: One group, in addition to fulfilling a hypocaloric diet identical to the control group, is subjected to prescribe moderate physical activity.~Other group, in addition to fulfilling a hypocaloric diet identical to the control and moderate group, is subjected to prescribe intense activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education, modifying diet and physical activity prescription
Description: One group, in addition to fulfilling a hypocaloric diet identical to the control group, is subjected to prescribe moderate physical activity.~Other group, in addition to fulfilling a hypocaloric diet identical to the control and moderate group, is subjected to prescribe intense activity.
Study: NCT03488680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior change communication
Description: Behavior change communication about optimal complementary feeding
Study: NCT01441219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colon 2
Description: Ingest one colon 2 capsule
Study: NCT01267773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Treatment
Study: NCT03204162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPR Coaching
Description: Teams in the experimental arm will have a member of their team assigned to be the CPR Coach. This person will provide CPR Coaching in the form of feedback in CPR quality (depth, rate) to the CPR providers as well as provide guidance on time for defibrillation, etc.
Study: NCT00872053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anklebot
Description: The Anklebot is a robotic device that is worn via a leather boot and knee brace (Fig.1). As the participant goes through a series of ankle-training games, the Anklebot can assist ankle movement throughout 3 planes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anklebot
Description: The Anklebot is a robotic device that is worn via a leather boot and knee brace (Fig.1). As the participant goes through a series of ankle-training games, the Anklebot can assist ankle movement throughout 3 planes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill. Attached to the lower limbs, the Lokomat moves the subject's legs over a treadmill through position controlled trajectories that mimic normal human gait patterns.
Study: NCT00224744

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultracision
Description: Surgery by Ultracision

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: classical lymphadenectomy
Description: classical lymphadenectomy
Study: NCT00148668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: One dose given followed by an MRI, then weekly injections beginning week 3 and ending week 14.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: One dose given followed by an MRI, then weekly injections beginning week 3 and ending week 14.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Navelbine
Description: Weekly injections given starting week 3 and ending week 14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere
Description: Given every three weeks starting week 3 and ending on week 14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given every three weeks starting week 3 and ending on week 14
Study: NCT03214770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TheraCal
Description: Biomaterial used for carious lesions reaching to dentin. Material is applied and after 6 month dentin sample collection and the bacterial count by digital colony counter, Agar diffusion test.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: light-cured calcium hydroxide
Description: Biomaterial used for carious lesions reaching to dentin. Material is applied and after 6 month dentin sample collection and the bacterial count by digital colony counter, Agar diffusion test.
Study: NCT03853551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib is an oral, potent, selective, irreversible inhibitor of both epidermal growth factor receptor - Tyrosine kinase inhibitors (EGFR-TKI) sensitizing and resistance mutations in nonsmall cell lung cancer (NSCLC) with a significant selectivity margin over wild-type EGFR.
Study: NCT01249846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PerioChip ®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PerioChip ®
Study: NCT03120429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fish group
Description: Fish group will have hypoenergetic diet in which subjects will have 3 x 150 g lean fish/ week at main meal

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: Control group will have hypo-energetic diet in which subjects have no seafood.
Study: NCT04727138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXS21546 Powder for Oral Suspension
Description: EXS21546 Powder for Oral Suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXS21546 Granule in Capsule
Description: EXS21546 Granule in Capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Interaction

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Interaction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Effect
Description: Fed/Fasted

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Effect
Description: Fed/Fasted

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Food Effect
Description: Fed/Fasted

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder for Oral Suspension
Description: Placebo Powder for Oral Suspension
Study: NCT01653600

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: S.M.A.R.T CONTROL Stent
Description: Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of \>15 mmHg, residual stenosis of \>30%, and flow-limiting dissection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeStent
Description: same to SMART STENT
Study: NCT03529708

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D CRT plus SBRT boost
Description: Patients will receive urgent standard 3D conformal radiotherapy (3D CRT) of plus stereotactic boost to tumor causing spinal cord compression (SCC). Initial dose for 3D CRT will be either 8Gy in 1 fraction or 20Gy in 5 fractions, with SBRT boost dose15Gy in 2 fractions of 12Gy in 2 fractions (depending on 8Gy/1 or 20Gy/5 initial RT dose respectively), delivered within three weeks of first treatment.
Study: NCT05509101

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: commercially available control algorithm
Description: Control of the prosthesis/orthosis is based on clinical standard of care using commercially available control algorithms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental control algorithm
Description: Control of the orthosis is based on residual muscle activity mapped to intended movement using high density electromyography and artificial intelligence control algorithms.
Study: NCT02028780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to dose
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarucizumab
Description: short infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Idarucizumab
Description: Placebo to Idarucizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran
Description: 2 capsules dabigatran

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarucizumab
Description: short infusion
Study: NCT01510964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prompt-sheet
Description: Prompt sheet is a form on which to write the reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist and a written list of possible questions the patient (companion) would like to ask to the oncology.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: control group
Description: Patients and companions of the control group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist
Study: NCT02855710

Intervention type: OTHER
Group type: OTHER
Intervention: Rhythm workers training Perceptive timing
Description: Perceptive timing training

Intervention type: OTHER
Group type: OTHER
Intervention: Rhythm workers training Perceptive timing
Description: Perceptive timing training

Intervention type: OTHER
Group type: OTHER
Intervention: Rhythm workers training sensorimotor timing
Description: Sensorimotor timing training

Intervention type: OTHER
Group type: OTHER
Intervention: No Rhythm workers training
Description: No training
Study: NCT02484768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000
Description: Intravenous treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Intravenous treatment
Study: NCT01168609

Intervention type: PROCEDURE
Intervention: Primary percutaneous coronary intervention
Description: Primary percutaneous coronary intervention (PCI) and stenting were performed for just the culprit lesion using standard techniques and bare-metal stents in all patients. Unfractionated heparin was used for 3 days after PCI, except in some cases with contraindications, and the dose of unfractionated heparin was selected to prolong the activated partial thromboplastin time by 2-3 times. The decision to use glycoprotein IIb/IIIa inhibitors was left to the discretion of the treating physician. The measurements of LVFP were performed via a fluid-filled pig-tail catheter placed into the LV after coronary angiography if PCI was not indicated or after primary PCI.
Study: NCT03457324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JCM-16021
Description: This prescription with seven ingredients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04446429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proxalutamide
Description: 200 mg q.d.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care as determined by the PI
Study: NCT03005639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib and Cobimetinib
Description: All participants will receive study treatment for up to 56 days (8 weeks). After completing treatment, they will undergo a lymph node removal surgery. After surgery, they will have follow-up visit 2-4 weeks after surgery.
Study: NCT00179764

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Immunoablative Hematopoietic PBSC Transplant
Description: Immunoablative conditioning chemotherapy regimen, followed by transplantation of peripheral blood stem cells on Day 0 of the conditioning regimen.
Study: NCT03845270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab + trastuzumab + docetaxel
Description: Cycle 1 : D1 : pertuzumab 840 mg, D2 : trastuzumab 8 mg/kg + docetaxel 75 mg/m² Subsequent cycle : D1 : pertuzumab 420 mg + trastuzumab 6 mg/kg + docetaxel 75 mg/m²
Study: NCT01088542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communities That Care
Description: The Communities That Care (CTC) system provides communities training and ongoing technical assistance in a structured process for conducting prevention needs assessments using epidemiological data on levels of risk and protective factors for adolescent problem behaviors, selection of tested and effective preventive interventions shown to address community-prioritized factors, implementation of these interventions with fidelity, and evaluation of the community's progress toward its goals. The CTC system is designed to produce a plan for prevention services that is tailored to the needs of each community. CTC is installed in five phases through a manualized series of training events designed to build the capacity of communities to install and sustain the system over time.
Study: NCT00179764

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Busulfan pharmacokinetics
Description: Pharmacokinetics of once-a-day dosing of intravenous busulfan as a 3-hour infusion

Intervention type: RADIATION
Group type: OTHER
Intervention: Central Nervous System (CNS) prophylaxis radiation
Description: * Patients diagnosed with ALL over 1 year of age and without prior CNS disease will receive CNS prophylaxis radiation to the whole brain prior to transplant.~* Patients diagnosed with ALL with prior CNS disease over the age of 1 year will be treated with prophylaxis radiation to the whole brain and spine prior to transplant.
Study: NCT02675257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes-related affective problems analysis
Description: Analysis of diabetes-related affective problems with regard to suboptimal glycaemic control
Study: NCT03846544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitoropin alfa (CFA)-double pick up
Description: In the study group, 225 IU of recombinant FSH (rFSH) will continue after the first oocyte retrieval (OR). Antagonist administration will be initiated when at least one follicle measuring ≥14 mm will be present in the ultrasound. If one or more follicles ≥17 mm are observed, patients will undergo a second triggering with human chorionic gonadotropin (hCG) 5000 IU and a second OR will be performed. In case of patients with no follicular development following 10 additional days of rFSH post-OR
Study: NCT03839615

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guided bone regenerations
Description: intra oral procedures.~* Flap will be done.~* In the study group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks.~* In the control group: : bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral and packed at the defected area then covered by a titanium reinforced polytetraflouroethelene membrane which will be stabilized by tacks.~* The site will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: guided bone regenerations
Description: intra oral procedures.~* Flap will be done.~* In the study group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks.~* In the control group: : bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral and packed at the defected area then covered by a titanium reinforced polytetraflouroethelene membrane which will be stabilized by tacks.~* The site will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures.
Study: NCT01247675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-001 (TransCon hGH)
Description: s.c., weekly injection
Study: NCT00981253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMT-enhanced Cardiac Rehabilitation
Description: Standard exercise-based cardiac rehabilitation, three times per week, enhanced with weekly stress management training for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cardiac Rehabilitation
Description: Supervised exercise, three times per week, for 12 weeks.
Study: NCT02390622

Intervention type: OTHER
Group type: OTHER
Intervention: Fecal microbiota transplantation
Description: bacteria liquid from 60g fecal was infusion via nasointestinal tube for three days
Study: NCT02675257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal setting towards improvement of glycaemic control
Description: Discussing and setting goals regarding improvements of suboptimal glycaemic control, depressive symptoms and diabetes distress
Study: NCT04319484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: 1-2 months after liver transplantation, participants are given lenvatinib with an initial dose of 8 mg (body weight \< 60 kg) or 12 mg orally once a day. The initial dose was 8 mg (body weight \< 60 kg) or 12 mg orally once a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-2 months after liver transplantation, participants are given Placebo with an initial dose of 8 mg (body weight \< 60 kg) or 12 mg orally once a day. The initial dose was 8 mg (body weight \< 60 kg) or 12 mg orally once a day.
Study: NCT02058056

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Irradiation: HA-PCI
Description: 25 Gy in 10 daily factions, five times a week
Study: NCT02959905

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TSA-CTL
Description: Patients will receive TSA-CTL iv over 20-30 minutes on day 0.
Study: NCT02675257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes-specific problem-solving therapy
Description: Diabetes-specific problem-solving therapy with main focus on suboptimal glycaemic control, depressive symptoms and diabetes distress
Study: NCT01247675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-001 (TransCon hGH)
Description: s.c., weekly injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-001 (TransCon hGH)
Description: s.c., weekly injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omnitrope
Description: s.c., daily injection
Study: NCT00621725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2171
Description: Oral dose
Study: NCT01763203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Management+Community Health Worker
Description: Over a period of a year subjects randomized into the Intervention arm of the study will receive support from a Care Manager. Subjects will also participate in educational group sessions on chronic disease self-management and have home visits by a Community Health Worker who will use mobile health technology.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Subjects randomized into the Usual Care arm will receive educational materials about stroke distributed to the Intervention patients and will receive their post-stroke care as usual.
Study: NCT02985021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Chemotherapy
Study: NCT03180957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline